Deku is a ‘super drug’ for depression

Professional Team

The company is one of the world’s largest pharmaceutical companies.

Its shares jumped nearly 6 percent on Thursday after the company announced a $20 million deal with the National Institutes of Health to help develop a new treatment for severe depression.

Deku shares have surged nearly 60 percent this year.

It’s a rare drug company that has not only a big financial stake in the treatment, but also has some significant political clout in Congress.

The company has pushed the drug on Congress for years, and it is now spending tens of millions of dollars to help the National Institute of Mental Health develop new treatments.

The FDA has been pushing for Deku to be approved as a treatment for major depression for years.

Dehuos chief executive, Richard H. Anderson, said the company has been working with the NIH to make the drug safer and more effective.

He also said that the company is committed to making the drug available to the public.

Dehuzodix has been available for use for more than three decades, but the FDA approved it in the late 1990s.

The drug has been linked to serious side effects, including seizures, psychosis and suicide.

“This is a major step forward for our efforts to develop and bring to market the next generation of effective antidepressants for depression,” said Hilda Fischman, director of the National Center for Advancing Translational Sciences at NIH.

Dehydroepiandrosterone acetate is the active ingredient in the drug.

In the US, Dehuo is approved for use in the acute phase of a bipolar disorder or for treatment of the severe depressive episode.

Deuos has been one of several major pharmaceutical companies to push for Dehuolizumab to be cleared for use as a depression treatment.

The Food and Drug Administration approved the drug in the US in 2016, and a US Senate panel approved it for human trials in June.

Dehwuzo is a different drug.

The National Institute for Mental Health has said the drug works by targeting a protein in the brain called BDNF.

BDNF is known to play a key role in depression and other mental health conditions, such as anxiety and psychosis.

The NIH’s approval of Dehuocet means it is available for clinical trials in the United States.

Deuzolizmab is a new medication that is different from the drug Dehhuoluzomab.

The new drug is designed to treat depression in patients with the most severe forms of depression.

It was developed by the US company Synthroid Inc. Synthoid also has a major financial stake with the FDA, and the company said it has spent millions of euros on research.

“We are excited to continue developing Dehuolizomab and hope to continue providing this important treatment for patients,” Synthrol said in a statement.

, ,